Levin Victor A, Tonge Peter J, Gallo James M, Birtwistle Marc R, Dar Arvin C, Iavarone Antonio, Paddison Patrick J, Heffron Timothy P, Elmquist William F, Lachowicz Jean E, Johnson Ted W, White Forest M, Sul Joohee, Smith Quentin R, Shen Wang, Sarkaria Jann N, Samala Ramakrishna, Wen Patrick Y, Berry Donald A, Petter Russell C
Kaiser Permanente, Redwood City, California, USA (V.A.L.); University of Texas MD Anderson Cancer Center, Houston, TX, USA (V.A.L.); University of California, San Francisco, CA, USA (V.A.L.); SUNY Stony Brook University, Stony Brook, NY, USA (P.J.T.); Icahn School of Medicine at Mount Sinai, New York, NY, USA (J.M.G., M.R.B., A.C.D.); Columbia University Institute for Cancer Genetics, New York, NY, USA (A.I.); Fred Hutchinson Cancer Research Center, Seattle, WA, USA (P.J.P.); Genentech, Inc., South San Francisco, CA, USA (T.P.H.); University of Minnesota School of Pharmacy, Minneapolis, MN, USA (W.F.E.); Angiochem, Inc., Montreal, Quebec, Canada (J.E.L.); Pfizer Oncology, San Diego, CA, USA (T.W.J.); Massachusetts Institute of Technology, Cambridge, MA, USA (F.M.W.); US Food and Drug Administration, Silver Spring, MD, USA (J.S.); Texas Tech University School of Pharmacy, Amarillo, TX, USA (Q.R.S., R.S.); NewGen Therapeutics, Inc., Menlo Park, CA, USA (W.S.); Mayo Clinic, Rochester, MN, USA (J.N.S.); Dana-Farber Cancer Institute, Boston, MA, USA (P.Y.W.); University of Texas MD Anderson Cancer Center, Houston, TX, USA (D.A.B.); Celgene Avilomics Research, Bedford, MA, USA (R.C.P.).
Neuro Oncol. 2015 Nov;17 Suppl 6(Suppl 6):vi1-26. doi: 10.1093/neuonc/nov169.
Following the first CNS Anticancer Drug Discovery and Development Conference, the speakers from the first 4 sessions and organizers of the conference created this White Paper hoping to stimulate more and better CNS anticancer drug discovery and development. The first part of the White Paper reviews, comments, and, in some cases, expands on the 4 session areas critical to new drug development: pharmacological challenges, recent drug approaches, drug targets and discovery, and clinical paths. Following this concise review of the science and clinical aspects of new CNS anticancer drug discovery and development, we discuss, under the rubric "Accelerating Drug Discovery and Development for Brain Tumors," further reasons why the pharmaceutical industry and academia have failed to develop new anticancer drugs for CNS malignancies and what it will take to change the current status quo and develop the drugs so desperately needed by our patients with malignant CNS tumors. While this White Paper is not a formal roadmap to that end, it should be an educational guide to clinicians and scientists to help move a stagnant field forward.
在首届中枢神经系统抗癌药物发现与开发会议之后，前四场会议的发言者以及会议组织者撰写了本白皮书，希望能推动更多更好的中枢神经系统抗癌药物的发现与开发。白皮书的第一部分对新药开发至关重要的四个会议领域进行了回顾、评论，在某些情况下还进行了扩展：药理学挑战、近期药物研发方法、药物靶点与发现以及临床路径。在对中枢神经系统抗癌新药发现与开发的科学和临床方面进行了简要回顾之后，我们在“加速脑肿瘤药物发现与开发”这一主题下，进一步探讨了制药行业和学术界未能开发出针对中枢神经系统恶性肿瘤的新型抗癌药物的原因，以及改变当前现状并开发出我们中枢神经系统恶性肿瘤患者急需的药物需要采取哪些措施。虽然本白皮书并非实现这一目标的正式路线图，但它应该是临床医生和科学家的教育指南，以帮助推动这个停滞不前的领域向前发展。
